698 related articles for article (PubMed ID: 33319454)
1. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Kosiborod M; Berwanger O; Koch GG; Martinez F; Mukhtar O; Verma S; Chopra V; Javaheri A; Ambery P; Gasparyan SB; Buenconsejo J; Sjöström CD; Langkilde AM; Oscarsson J; Esterline R
Diabetes Obes Metab; 2021 Apr; 23(4):886-896. PubMed ID: 33319454
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kosiborod MN; Esterline R; Furtado RHM; Oscarsson J; Gasparyan SB; Koch GG; Martinez F; Mukhtar O; Verma S; Chopra V; Buenconsejo J; Langkilde AM; Ambery P; Tang F; Gosch K; Windsor SL; Akin EE; Soares RVP; Moia DDF; Aboudara M; Hoffmann Filho CR; Feitosa ADM; Fonseca A; Garla V; Gordon RA; Javaheri A; Jaeger CP; Leaes PE; Nassif M; Pursley M; Silveira FS; Barroso WKS; Lazcano Soto JR; Nigro Maia L; Berwanger O
Lancet Diabetes Endocrinol; 2021 Sep; 9(9):586-594. PubMed ID: 34302745
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.
Moustafa DA; Imran Z; Ismail R; Rayan M; Gadeau AP; Eldassouki H; Abdulrahman N; Mraiche F
Mol Biol Rep; 2022 Mar; 49(3):2321-2324. PubMed ID: 35102475
[TBL] [Abstract][Full Text] [Related]
4. Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept.
Anastasiou G; Hatziagelaki E; Liberopoulos E
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e12-e19. PubMed ID: 34001719
[TBL] [Abstract][Full Text] [Related]
5. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Shigiyama F; Kumashiro N; Fuchigami A; Hirose T
Cardiovasc Diabetol; 2018 Jun; 17(1):86. PubMed ID: 29895330
[TBL] [Abstract][Full Text] [Related]
7. Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
Yu MK; Vart P; Jongs N; Correa-Rotter R; Rossing P; McMurray JJV; Hou FF; Douthat W; Khullar D; Langkilde AM; Wheeler DC; Heerspink HJL; Chertow GM
J Gen Intern Med; 2024 May; 39(6):921-930. PubMed ID: 38097862
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial.
Heerspink HJL; Furtado RHM; Berwanger O; Koch GG; Martinez F; Mukhtar O; Verma S; Gasparyan SB; Tang F; Windsor SL; de Souza-Dantas VC; Del Sueldo M; Frankel R; Javaheri A; Maldonado RA; Morse C; Mota-Gomes M; Shemin D; Silva OL; Tognon AP; Twahirwa M; Buenconsejo J; Esterline R; Oscarsson J; Ambery P; Langkilde AM; Kosiborod MN
Clin J Am Soc Nephrol; 2022 May; 17(5):643-654. PubMed ID: 35483733
[TBL] [Abstract][Full Text] [Related]
9. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Cox ZL; Collins SP; Aaron M; Hernandez GA; Iii ATM; Davidson BT; Fowler M; Lindsell CJ; Jr FEH; Jenkins CA; Kampe C; Miller KF; Stubblefield WB; Lindenfeld J
Am Heart J; 2021 Feb; 232():116-124. PubMed ID: 33144086
[TBL] [Abstract][Full Text] [Related]
11. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
12. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Zelniker TA; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS;
N Engl J Med; 2019 Jan; 380(4):347-357. PubMed ID: 30415602
[TBL] [Abstract][Full Text] [Related]
14. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
[TBL] [Abstract][Full Text] [Related]
16. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
17. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
[TBL] [Abstract][Full Text] [Related]
19. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
McMurray JJV; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD;
Eur J Heart Fail; 2019 May; 21(5):665-675. PubMed ID: 30895697
[TBL] [Abstract][Full Text] [Related]
20. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
